<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>dose &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/dose/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 12:54:21 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>dose &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Liraglutide Doses Below 3.0 mg Show Real-World Benefit, but Cost Blocks Half of Patients</title>
		<link>https://bioengineer.org/liraglutide-doses-below-3-0-mg-show-real-world-benefit-but-cost-blocks-half-of-patients/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 12:54:21 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[affordability]]></category>
		<category><![CDATA[dose]]></category>
		<category><![CDATA[drug affordability]]></category>
		<category><![CDATA[durability]]></category>
		<category><![CDATA[GLP-1 receptor agonists]]></category>
		<category><![CDATA[health equity]]></category>
		<category><![CDATA[liraglutide]]></category>
		<category><![CDATA[obesity]]></category>
		<category><![CDATA[Real]]></category>
		<category><![CDATA[Real-world evidence]]></category>
		<category><![CDATA[Taiwan]]></category>
		<category><![CDATA[weight management]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=427283</guid>

					<description><![CDATA[A Taiwanese post-marketing surveillance study finds that nearly half of patients who failed to reach the approved 3.0 mg liraglutide dose cited cost, prompting calls for personalised dosing and equity-focused policy.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">427283</post-id>	</item>
		<item>
		<title>Clesrovimab: a single-dose antibody reshapes RSV prevention for infants</title>
		<link>https://bioengineer.org/clesrovimab-a-single-dose-antibody-reshapes-rsv-prevention-for-infants/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 11:36:36 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[chance]]></category>
		<category><![CDATA[Clesrovimab]]></category>
		<category><![CDATA[dose]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[scientific research]]></category>
		<category><![CDATA[Season]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=426459</guid>

					<description><![CDATA[Respiratory syncytial virus, or RSV, has been a stubborn adversary of infant health for decades. It remains a leading cause of lower respiratory tract infection and hospitalization in babies worldwide, and for most of that history prevention was limited to]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">426459</post-id>	</item>
	</channel>
</rss>
